Q: What is Injectafer used for?

Injectafer is used to treat iron deficiency anemia in: Adults and pediatric patients ≥1 year with intolerance/unsatisfactory response to oral iron Adults with non-dialysis-dependent chronic kidney disease Adults with heart failure (NYHA class II/III) to improve exercise capacity

Q: How does Injectafer work?

Mechanism of Action Injectafer contains ferric carboxymaltose, which is a complex consisting of an iron core surrounded by a carbohydrate shell. This specific structure is designed to allow the iron to be released in a controlled manner into the body's systems after it is administered through an intravenous (IV) injection or infusion. Iron is an essential mineral that the body requires for several vital functions: Hemoglobin Production: Iron is a primary component of hemoglobin, the protein in red blood cells responsible for carrying oxygen from the lungs to the rest of the body. Oxygen Transport: By increasing the amount of iron available, Injectafer helps the body produce more red blood cells, which improves the delivery of oxygen to tissues and organs. Iron Storage: The iron provided by the medication can be stored by the body in the liver, bone marrow, and spleen. These stores are used as needed to maintain healthy blood levels. This medication is typically used for patients who cannot take iron supplements by mouth or for whom oral iron has not been effective.

Q: What are the active ingredients in Injectafer?

The active ingredient in Injectafer is ferric carboxymaltose .

Q: What are the side effects of Injectafer?

Common side effects of Injectafer may include: Nausea Hypertension Flushing and others. Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Injectafer and how do I take it?

Administration Injectafer is given directly into a vein by a healthcare professional in a clinical setting, such as a doctor's office, clinic, or hospital. It may be administered as a slow intravenous injection or as an infusion over several minutes. Dosing Schedule The treatment schedule is determined by a healthcare provider based on the patient's body weight and the specific condition being treated. Common administration patterns include: Two separate doses given at least seven days apart. A single dose for certain patients based on weight and clinical needs. Blood tests may be performed regularly to monitor iron levels and determine if additional treatment cycles are necessary. Monitoring After receiving a dose, patients are typically monitored for at least 30 minutes by medical staff to watch for any signs of an immediate reaction or hypersensitivity. It is important to inform the healthcare provider immediately if any unusual symptoms occur during or after the infusion. Missed Dose Because this medication is administered by a healthcare provider, it is important to keep all scheduled appointments. If a dose is missed, contact the healthcare provider's office as soon as possible to reschedule the treatment.

Q: Is Injectafer safe during pregnancy and breastfeeding?

Pregnancy Iron deficiency anemia is common during pregnancy and, if left untreated, can increase the risk of complications such as preterm delivery and low birth weight. Injectafer is typically used when oral iron supplements have not worked or are not an option. Available data from clinical studies have not identified a clear risk of major birth defects or miscarriage associated with the use of this medication during pregnancy. Breastfeeding Small amounts of iron from Injectafer pass into breast milk. Based on current evidence, the amount of iron absorbed by a nursing infant is expected to be low and is not likely to cause adverse effects. There is no evidence that the medication impacts the production of breast milk. Clinical Considerations Healthcare providers weigh the risks of untreated anemia against the potential effects of the medication. Key points for consideration include: The severity of the iron deficiency and the stage of pregnancy. The patient's ability to tolerate oral iron alternatives. The risk of hypersensitivity reactions, which can occur with intravenous iron and require medical monitoring during administration. Patients should inform their doctor if they are pregnant, planning to become pregnant, or breastfeeding to ensure the most appropriate treatment plan is developed.

Q: What is the FDA approval status of Injectafer?

FDA Approval and Indications Injectafer (ferric carboxymaltose injection) is approved by the FDA for the treatment of iron deficiency anemia in adults who have had an unsatisfactory response to oral iron or who cannot tolerate oral iron therapy. It is also approved for use in adult patients with non-dialysis dependent chronic kidney disease. The FDA has also approved Injectafer for pediatric patients aged 1 year and older who have iron deficiency anemia and meet the same criteria regarding oral iron intolerance or lack of effectiveness. Regulatory Safety Communications The FDA has issued safety communications to strengthen warnings regarding the risk of symptomatic hypophosphatemia, which is a condition where phosphate levels in the blood become abnormally low. This risk was identified through the FDA Adverse Event Reporting System and led to changes in the prescribing information. Prescribing instructions now include recommendations for healthcare providers to monitor serum phosphate levels in patients who are at risk for low phosphate or those who require repeat courses of the medication. Risk factors for this condition may include malnutrition, vitamin D deficiency, or certain bone disorders. Monitoring and Precautions While Injectafer does not have a boxed warning, the FDA requires labeling to include precautions regarding serious hypersensitivity reactions. These allergic reactions, including anaphylaxis, can be life-threatening and may occur even if a patient has previously tolerated the medication. Regulatory guidelines suggest that patients should be monitored by healthcare professionals for at least 30 minutes following each infusion to watch for signs of a reaction.

Question 1

What is Injectafer?

Accepted Answer

Injectafer is a prescription medication that serves as an iron replacement product. It contains ferric carboxymaltose, which is a form of iron that the body can use to maintain healthy levels of this essential mineral.

Iron is a vital component required for the production of hemoglobin, the protein in red blood cells that carries oxygen to tissues and organs. This medication helps replenish iron stores when they have become depleted.

Question 2

What is Injectafer used for?

Accepted Answer

Injectafer is used to treat iron deficiency anemia in:

Adults and pediatric patients ≥1 year with intolerance/unsatisfactory response to oral iron
Adults with non-dialysis-dependent chronic kidney disease
Adults with heart failure (NYHA class II/III) to improve exercise capacity

Question 3

How does Injectafer work?

Accepted Answer

Mechanism of Action

Injectafer contains ferric carboxymaltose, which is a complex consisting of an iron core surrounded by a carbohydrate shell. This specific structure is designed to allow the iron to be released in a controlled manner into the body's systems after it is administered through an intravenous (IV) injection or infusion.

Iron is an essential mineral that the body requires for several vital functions:

Hemoglobin Production: Iron is a primary component of hemoglobin, the protein in red blood cells responsible for carrying oxygen from the lungs to the rest of the body.
Oxygen Transport: By increasing the amount of iron available, Injectafer helps the body produce more red blood cells, which improves the delivery of oxygen to tissues and organs.
Iron Storage: The iron provided by the medication can be stored by the body in the liver, bone marrow, and spleen. These stores are used as needed to maintain healthy blood levels.

This medication is typically used for patients who cannot take iron supplements by mouth or for whom oral iron has not been effective.

Question 4

What are the active ingredients in Injectafer?

Accepted Answer

The active ingredient in Injectafer is ferric carboxymaltose.

Question 5

What are the side effects of Injectafer?

Accepted Answer

Common side effects of Injectafer may include:

Nausea
Hypertension
Flushing
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Injectafer?

Accepted Answer

Injectafer belongs to the intravenous iron replacement drug class.

Question 7

What is the dosage of Injectafer and how do I take it?

Accepted Answer

Administration

Injectafer is given directly into a vein by a healthcare professional in a clinical setting, such as a doctor's office, clinic, or hospital. It may be administered as a slow intravenous injection or as an infusion over several minutes.

Dosing Schedule

The treatment schedule is determined by a healthcare provider based on the patient's body weight and the specific condition being treated. Common administration patterns include:

Two separate doses given at least seven days apart.
A single dose for certain patients based on weight and clinical needs.

Blood tests may be performed regularly to monitor iron levels and determine if additional treatment cycles are necessary.

Monitoring

After receiving a dose, patients are typically monitored for at least 30 minutes by medical staff to watch for any signs of an immediate reaction or hypersensitivity. It is important to inform the healthcare provider immediately if any unusual symptoms occur during or after the infusion.

Missed Dose

Because this medication is administered by a healthcare provider, it is important to keep all scheduled appointments. If a dose is missed, contact the healthcare provider's office as soon as possible to reschedule the treatment.

Question 8

Is Injectafer safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Iron deficiency anemia is common during pregnancy and, if left untreated, can increase the risk of complications such as preterm delivery and low birth weight. Injectafer is typically used when oral iron supplements have not worked or are not an option. Available data from clinical studies have not identified a clear risk of major birth defects or miscarriage associated with the use of this medication during pregnancy.

Breastfeeding

Small amounts of iron from Injectafer pass into breast milk. Based on current evidence, the amount of iron absorbed by a nursing infant is expected to be low and is not likely to cause adverse effects. There is no evidence that the medication impacts the production of breast milk.

Clinical Considerations

Healthcare providers weigh the risks of untreated anemia against the potential effects of the medication. Key points for consideration include:

The severity of the iron deficiency and the stage of pregnancy.
The patient's ability to tolerate oral iron alternatives.
The risk of hypersensitivity reactions, which can occur with intravenous iron and require medical monitoring during administration.

Patients should inform their doctor if they are pregnant, planning to become pregnant, or breastfeeding to ensure the most appropriate treatment plan is developed.

Question 9

What forms and strengths does Injectafer come in?

Accepted Answer

Injectafer is supplied as a liquid solution for administration into a vein. It is available in the following format:

Intravenous Injection: A sterile solution provided in single-dose vials for injection or infusion.

This medication is administered only by a healthcare professional in a clinical setting.

Question 10

What is the FDA approval status of Injectafer?

Accepted Answer

FDA Approval and Indications

Injectafer (ferric carboxymaltose injection) is approved by the FDA for the treatment of iron deficiency anemia in adults who have had an unsatisfactory response to oral iron or who cannot tolerate oral iron therapy. It is also approved for use in adult patients with non-dialysis dependent chronic kidney disease.

The FDA has also approved Injectafer for pediatric patients aged 1 year and older who have iron deficiency anemia and meet the same criteria regarding oral iron intolerance or lack of effectiveness.

Regulatory Safety Communications

The FDA has issued safety communications to strengthen warnings regarding the risk of symptomatic hypophosphatemia, which is a condition where phosphate levels in the blood become abnormally low. This risk was identified through the FDA Adverse Event Reporting System and led to changes in the prescribing information.

Prescribing instructions now include recommendations for healthcare providers to monitor serum phosphate levels in patients who are at risk for low phosphate or those who require repeat courses of the medication. Risk factors for this condition may include malnutrition, vitamin D deficiency, or certain bone disorders.

Monitoring and Precautions

While Injectafer does not have a boxed warning, the FDA requires labeling to include precautions regarding serious hypersensitivity reactions. These allergic reactions, including anaphylaxis, can be life-threatening and may occur even if a patient has previously tolerated the medication. Regulatory guidelines suggest that patients should be monitored by healthcare professionals for at least 30 minutes following each infusion to watch for signs of a reaction.

Question 11

What should I know about Injectafer and cost?

Accepted Answer

Factors Affecting Cost

The total price for Injectafer treatment is influenced by several variables:

Insurance Coverage: Most insurance plans, including Medicare, typically cover Injectafer when it is medically necessary. However, your specific plan will determine your out-of-pocket costs, such as copayments, coinsurance, or deductibles.
Dosage: The amount of medication required is determined by your body weight and the severity of your iron deficiency. Higher doses or multiple sessions will increase the overall cost.
Administration Fees: Because Injectafer is administered as an intravenous (IV) infusion by a healthcare professional, you will likely incur costs for the clinic or hospital visit and the professional services provided, in addition to the cost of the drug itself.

Generic Availability

Injectafer is a brand-name medication. There is currently no generic version of ferric carboxymaltose available in the United States. Brand-name drugs typically cost more than generic alternatives.

Financial Assistance Programs

The manufacturer may offer patient assistance programs or savings cards to help eligible individuals manage their out-of-pocket expenses. Patients should contact their insurance provider or the manufacturer directly to explore available financial support options.

Injectafer

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Injectafer

Hospitals.net Disclosure